Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YTHDC1 | Q96MU7 | 2/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.32 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.32 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.32 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17314970 | 1.00 | YTHDC1 (0.38) | YTHDC1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL15931226 | 0.86 | YTHDC1 (0.40) | YTHDC1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL17314102 | 0.86 | YTHDC1 (0.40) | YTHDC1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL15931509 | 0.86 | YTHDC1 (0.40) | YTHDC1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL17314940 | 0.86 | YTHDC1 (0.40) | YTHDC1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL20105702 | 0.86 | YTHDC1 (0.50) | YTHDC1CYP11B2 | |
| SCHEMBL17314945 | 0.86 | YTHDC1 (0.41) | YTHDC1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL15931214 | 0.86 | YTHDC1 (0.41) | YTHDC1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL15942192 | 0.83 | YTHDC1 (0.37) | YTHDC1CYP11B2 | |
| SCHEMBL15921610 | 0.82 | YTHDC1 (0.39) | YTHDC1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2951180-B1 | 2,6,7,8 SUBSTITUTED PURINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME (US) | 2018-05-02 | — | — | EP | disclosed |
| US-9540377-B2 | 2,6,7,8 substituted purines as HDM2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-01-10 | — | — | US | disclosed |
| US-20150353553-A1 | 2,6,7,8 SUBSTITUTED PURINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353553-A1 | 2,6,7,8 SUBSTITUTED PURINES AS HDM2 INHIBITORS | DDX21, DPYD, NSUN2 | YTHDC1 401/4885MAPK14 2784/4885MAPK13 3268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.